2 Oral: Preliminary results from SEACRAFT-1: An open-label study of naporafenib with trametinib in patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations
Titel:
2 Oral: Preliminary results from SEACRAFT-1: An open-label study of naporafenib with trametinib in patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations
Auteur:
Fontana, E. Spira, A.I. McKean, M. Lee, J. Chau, N. Winquist, E. Kim, I. Hong, S.H. Van Tine, B.A. Fawole, A. Shoemaker, R. Cui, Y. Sutton, R. Antal, J.M. Morris, S.R. Hong, D.S.